Skip to content

Study · Animal study (in vivo) · rat · 1992

4 results

Synergistic interaction between insulin-like growth factors-I and -II in central regulation of pulsatile growth hormone secretion.

Harel Z, Tannenbaum GS

Endocrinology1 Aug 1992Cited by 41 (Europe PMC)

PMID1639021 (opens in a new tab)DOI10.1210/endo.131.2.1639021 (opens in a new tab)PepBankPUB-01639021
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, central administration of long R3 IGF-I did not change GH peak amplitude compared with vehicle.

    In plain wordsIn rats, long R3 IGF-I given into the brain did not change growth hormone peak size compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeGH peak amplitude
    Study

    ratn: not reported in source

    Free-moving adult male rats with intracerebroventricular and intracardiac cannulae
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Central administration of IGF-I alone or long R3 IGF-I at all doses tested failed to alter the pulsatile pattern of GH release; there were no significant differences in GH peak amplitude, GH trough level, GH interpeak interval, or mean 6-h plasma GH level compared to those in vehicle-injected controls.
    1 context sentence
    Summary · context
    Five groups of free-moving adult male rats bearing chronic intracerebroventricular (icv) and intracardiac venous cannulae were icv administered IGF-I (in doses of 0.5, 2, 3, and 10 micrograms) or the acid-saline vehicle; an additional group received 1 microgram of the potent IGF-I analog, long R3 IGF-I.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, central administration of long R3 IGF-I did not change GH trough level compared with vehicle.

    In plain wordsIn rats, long R3 IGF-I given into the brain did not change growth hormone trough levels compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeGH trough level
    Study

    ratn: not reported in source

    Free-moving adult male rats with intracerebroventricular and intracardiac cannulae
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Central administration of IGF-I alone or long R3 IGF-I at all doses tested failed to alter the pulsatile pattern of GH release; there were no significant differences in GH peak amplitude, GH trough level, GH interpeak interval, or mean 6-h plasma GH level compared to those in vehicle-injected controls.
    1 context sentence
    Summary · context
    Five groups of free-moving adult male rats bearing chronic intracerebroventricular (icv) and intracardiac venous cannulae were icv administered IGF-I (in doses of 0.5, 2, 3, and 10 micrograms) or the acid-saline vehicle; an additional group received 1 microgram of the potent IGF-I analog, long R3 IGF-I.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, central administration of long R3 IGF-I did not change the GH interpeak interval compared with vehicle.

    In plain wordsIn rats, long R3 IGF-I given into the brain did not change the time between growth hormone peaks compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeGH interpeak interval
    Study

    ratn: not reported in source

    Free-moving adult male rats with intracerebroventricular and intracardiac cannulae
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Central administration of IGF-I alone or long R3 IGF-I at all doses tested failed to alter the pulsatile pattern of GH release; there were no significant differences in GH peak amplitude, GH trough level, GH interpeak interval, or mean 6-h plasma GH level compared to those in vehicle-injected controls.
    1 context sentence
    Summary · context
    Five groups of free-moving adult male rats bearing chronic intracerebroventricular (icv) and intracardiac venous cannulae were icv administered IGF-I (in doses of 0.5, 2, 3, and 10 micrograms) or the acid-saline vehicle; an additional group received 1 microgram of the potent IGF-I analog, long R3 IGF-I.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, central administration of long R3 IGF-I did not change mean 6-h plasma GH level compared with vehicle.

    In plain wordsIn rats, long R3 IGF-I given into the brain did not change average growth hormone levels over 6 hours compared with vehicle.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeMean 6-h plasma GH level
    Study

    ratn: not reported in source

    Free-moving adult male rats with intracerebroventricular and intracardiac cannulae
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Central administration of IGF-I alone or long R3 IGF-I at all doses tested failed to alter the pulsatile pattern of GH release; there were no significant differences in GH peak amplitude, GH trough level, GH interpeak interval, or mean 6-h plasma GH level compared to those in vehicle-injected controls.
    1 context sentence
    Summary · context
    Five groups of free-moving adult male rats bearing chronic intracerebroventricular (icv) and intracardiac venous cannulae were icv administered IGF-I (in doses of 0.5, 2, 3, and 10 micrograms) or the acid-saline vehicle; an additional group received 1 microgram of the potent IGF-I analog, long R3 IGF-I.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.